Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candida Antigen and Bivalent HPV Vaccine for Multiple Warts
NCT05291845Phase 2Recruiting
- Sponsor
- Zagazig University
- Start
- Apr 2022
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of candida albicans antigen, Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine in warts, sponsored by Zagazig University. Started Apr 2022; status: recruiting.
02
Drugs
candida albicans antigenHuman papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
03
Conditions
warts
Beyond the preview
Go deeper on NCT05291845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291845.